Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.13 USD | +6.16% | +35.38% | +23.84% |
04-30 | North American Morning Briefing : More Earnings -2- | DJ |
04-29 | Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 | MT |
Evolution of the average Target Price on PTC Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering PTC Therapeutics, Inc.
Morgan Stanley | |
TD Cowen | |
RBC Capital Markets | |
Cantor Fitzgerald | |
Barclays | |
Citigroup | |
Truist Securities | |
Goldman Sachs | |
JPMorgan Chase | |
Raymond James | |
UBS | |
Credit Suisse | |
BofA Securities | |
SVB Securities LLC | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- PTCT Stock
- Consensus PTC Therapeutics, Inc.